TD Asset Management’s Apogee Therapeutics APGE Stock Holding History

TD Asset Management’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.72M	Sell	20,474 -164,318	-89%	-$14.8M	﹤0.01%	915
2026 Q1	$15.6M	Buy	184,792 +55,502	+43%	+$4.03M	0.01%	553
2025 Q4	$9.76M	Buy	129,290 +46,050	+55%	+$2.9M	0.01%	661
2025 Q3	$3.31M	Sell	83,240 -11,348	-12%	-$433K	﹤0.01%	865
2025 Q2	$4.11M	Sell	94,588 -6,800	-7%	-$259K	﹤0.01%	792
2025 Q1	$3.79M	Sell	101,388 -25,058	-20%	-$969K	﹤0.01%	825
2024 Q4	$5.73M	Buy	126,446 +33,000	+35%	+$1.68M	0.01%	773
2024 Q3	$5.42M	Sell	93,446 -1,560	-2%	-$74.7K	﹤0.01%	779
2024 Q2	$3.74M	Sell	95,006 -53,200	-36%	-$2.58M	﹤0.01%	832
2024 Q1	$9.85M	Buy	148,206 +47,360	+47%	+$2.07M	0.01%	630
2023 Q4	$2.82M	Buy	100,846 +69,052	+217%	+$1.38M	﹤0.01%	901
2023 Q3	$677K	Buy	+31,794	New	+$700K	﹤0.01%	1218

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

TD Asset Management's APGE Position: Q2 2026 in Review

TD Asset Management reduced its Apogee Therapeutics (APGE) stake by 89% in Q2 2026, selling an estimated $14.8M and leaving 20,474 shares worth $2.72M. The position accounts for ﹤0.01% of the portfolio, ranked #915.

TD Asset Management first reported a position in APGE in Q3 2023 and has held it in 12 quarters since. The position peaked at $15.6M in Q1 2026. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

TD Asset Management held 20,474 shares of Apogee Therapeutics worth $2.72M as of Q2 2026.
TD Asset Management sold 164,318 Apogee Therapeutics shares in Q2 2026, an estimated $14.8M.
Apogee Therapeutics made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #915 holding.
TD Asset Management first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 12 quarters since.
TD Asset Management's Apogee Therapeutics position peaked at $15.6M in Q1 2026.
288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.